Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glasdegib PK in Renal Impairment
NCT03596567Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glasdegib in acute myeloid leukemia (AML) (3 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 6 days and Area Under the Curve From Time Zero to Extrapolated Infinite Time at 6 days. Started May 2018; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03596567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03596567.